Onvansertib T6247
Specifications
| 1mg/5mg/10mg/25mg/50mg/100mg |
Bioactivity:
NMS-P937 (NMS1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3.
CAS nr:
1034616-18-6
Purity:
98%
Molecular Weight:
532,52
SMILES:
CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1
Formula:
C24H27F3N8O3
Pathway:
Cell Cycle/Checkpoint,Apoptosis
Target:
PLK,Apoptosis
